Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-12
2010-06-22
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S328000, C546S242000
Reexamination Certificate
active
07741340
ABSTRACT:
The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.
REFERENCES:
patent: 5051407 (1991-09-01), Boshagen et al.
patent: 5580757 (1996-12-01), Desnick et al.
patent: 5658567 (1997-08-01), Calhoun et al.
patent: 6066626 (2000-05-01), Yew et al.
patent: 6083725 (2000-07-01), Selden et al.
patent: 6274597 (2001-08-01), Fan et al.
patent: 6335011 (2002-01-01), Podsakoff et al.
patent: 6583158 (2003-06-01), Fan et al.
patent: 6589964 (2003-07-01), Fan et al.
patent: 6599919 (2003-07-01), Fan et al.
patent: 6696059 (2004-02-01), Jacob et al.
patent: 6916829 (2005-07-01), Fan et al.
patent: 7141582 (2006-11-01), Fan et al.
patent: 2007/0021381 (2007-01-01), Fan et al.
patent: WO2004/037373 (2004-05-01), None
Zhu et. al. Angewandte Chemie International Edition English 2005, 44, 7450-7453.
Marina Jmoudiak and Anthony H. Futerman “Gaucher disease: pathological mechanisms and modern management” British Journal of Haematology, 2005, 129, 178-188.
U.S. National Library of Medicine Genetics Home Reference “GBA” online “http://ghr.nlm.nih.gov/gene=gba” Jun. 18, 2007.
A. R. Sawkar, W. D'Haeze and J. W. Kelly “Human Genome & Diseases: Review Therapeutic strategies to ameliorate lysosomal storage disorders—a focus on Gaucher disease” Cellular and Molecular Life Sciences 2006, 63, 1179-1192.
Wolff (Medicinal Chemistry) summarizes the state of the prodrug art. Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker (Modern Pharmaceutics) Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Asano, Naoki, et al. 2000. In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-by 1-deoxygalactonojiuimycin and its derivatives.Eur. J. Biochem. 267:4179-4186.
Best, Wayne M., et al. 2002. The synthesis of a carbohydrate-like dihydrooxazine and tetrahydrooxazine as putative inhibitors of glycoside hydrolases: A direct synthesis of isofagomine.Can. J. Chem. 80:857-865.
Bishop, David F., et al. 1986. Human α-galactosidase A: Nucleotide sequence of a cDNA clone encoding the mature enzyme.Proc. Natl. Acad. Sci. USA88:4859-4863.
Brady, Roscoe O., et al., 1965. Metabolism of Glucocerebrosides—II. Evidence of an Enzymatic Deficiency in Gaucher's Disease.Biochemical and Biophysical Research Communications18(2):221-225.
Burrows, Jon A.J., et al. 2000. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: A potential pharmacological strategy for prevention of livery injury and empnhysema in α1-AT deficiency.Proc. Natl. Acad. Sci. USA97(4):1796-1801.
Butters, Terry D., et al. 2003. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.Phil. Trans R. Soc. Lond. 358:927-945.
Cox, Timothy, et al. 2000. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.The Lancet355:1481-1485.
Dvir, Hay, et al. 2003. X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease.EMBO reports4(7):1-6.
Fan, Jian-Qiang, et al. 1999. Accelerated transport and maturation of lysosomal α -galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.Nature Medicine5(1)112-115.
Greenberg, Paul, et al. 1990. Human acid β-glucosidase: use of sphingosyl andN-alkyl-glucosylamine inhibitors to investigate the properties of the active site.Biochimica et Biophysica Acta1039:12-20.
Heightman, Tom D., and Vasella, Andrea T. 1999. Recent Insights into Inhibition, Structure, and Mechanism of Configuration-Retaining Glycosidases.Angew. Chem. Int. Ed. 38:750-770.
Ichikawa, Yoshitaka, et al. 1998. 1-N-Iminosugars: Potent and Selective Inhibitors of β-Glycosidases.J. Am. Chem. Soc. 120:3007-3018.
Inokuchi, Jin-ichi, and Radin, Norman S. 1987. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase.Journal of Lipid Research28:565-571.
Ishii, Satoshi, et al. 1993. Characterization of a Mutant α-Galactosidase Gene Product for the Late-Onset Cardiac Form of Fabry Disease.Biochemical and Biophysical Research Communications197(3):1585-1589.
Kim, Yong Jip, et al. 2000. Highly Selective Synthesis of 1-N-Iminosugars of the D-Glucose and -Glucuronic Acid Types.J. Org. Chem. 65:2599-2602.
Kohmura, Yoshinori, and Mase, Toshiaki. 2004. A Highly Stereoselective Synthesis of Optically Active Trisubstituted 1,2-Ethylenediamines: The First Example of Grignard Addition toN-Diphenylphosphinoyl Ketimines Derived from Amino Acids.J. Org. Chem. 69:6329-6334.
Lillelund, Vinni H., et al. 2002. Recent Developments of Transition-State Analogue Glycosidase Inhibitors of Non-Natural Product Origin.Chem. Rev. 102:515-553.
Ogawa, Seiichiro, et al. 1996. Synthesis of Potent β-D-Glucocerebrosidase Inhibitors: N-Alkyl-β-Valienamines.Bioorganic&Medicinal Chemistry Letters6(8):929-932.
Platt, Frances M., et al.N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not AffectN-Linked Oligosaccharide Processing.The Journal of Biological Chemistry269(43):27108-27114.
Platt, Frances M., and Butters, Terry D. 1998. New Therapeutic Prospects for the Glycosphingolipid Lysosomal Storage Diseases.Biochemical Pharmacology56:421-430.
Sawkar, Anu R., et al. 2002. Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher Disease.Proc. Natl. Aced. Sci. USA99(24):15428-15433.
Sawkar et al., “Chemical chaperones increase the cellular activity of N370S b-glucosidase: A therapeutic strategy for Gaucher disease,” PNAS, Nov. 26, 2002, vol. 99, No. 24, 15428-15433.
Priestman et al., “Imino sugar therapy for type 1 Gaucher disease,” Glycobiology. 2000; 11: iv-vi.
Panday et al., Very Strong Inhibition of Glucosidases by C(2)-Substituted Tetrahydroimidazopyridines, Helvetica Chimica Acta. 2000; 83: 58-79.
Plesner et al., Accurate Determination of Rate Constants of Very Slow, Tight-Binding Competitive Inhibitors by Numerical Solution of Differential Equations, Independently of Precise Knowledge of the Enzyme Concentration; Analytical Biochemistry. 2001; 295: 186-193.
Ruvinov et al., Monovalent Cations Partially Repair a Conformational Defect in a Mutant Tryptophan Synthase α2β2 Complex (β-E109A)*; J. Biol. Chem. 1995; 270: 17333-38.
Fan Jian-Qiang
Sheth Kamlesh
Zhu Xiaoxiang
Amicus Therapeutics, Inc.
Desai Rita J
Hoffmann & Baron , LLP
O'Dell David K
LandOfFree
Hydroxy piperidine derivatives to treat gaucher disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxy piperidine derivatives to treat gaucher disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxy piperidine derivatives to treat gaucher disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220995